Comparative Analysis of the Efficacy and Safety of Oxaliplatin Plus 5-Fluorouracil/Leucovorin (Modified FOLFOX6) with Advanced Gastric Cancer Patients having a Good or Poor Performance Status |
Hacibekiroglu, Ilhan
(Department of Medical Oncology, Faculty of Medicine, Trakya University)
Kodaz, Hilmi (Department of Medical Oncology, Faculty of Medicine, Trakya University) Erdogan, Bulent (Department of Medical Oncology, Faculty of Medicine, Trakya University) Turkmen, Esma (Department of Medical Oncology, Faculty of Medicine, Trakya University) Esenkaya, Asim (Department of Radiology, Faculty of Medicine, Trakya University) Uzunoglu, Sernaz (Department of Medical Oncology, Faculty of Medicine, Trakya University) Cicin, Irfan (Department of Medical Oncology, Faculty of Medicine, Trakya University) |
1 | Chau I, Norman AR, Cunningham D, et al (2004). Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol, 22, 2395-403. DOI |
2 | Cirillo M, Venturini M, Ciccarelli L, et al (2009). Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire. Ann Oncol, 20, 1929-35. DOI |
3 | de Gramont A, Figer A, Seymour M, et al (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18, 2938-47. |
4 | De Vita F, Orditura M, Matano E, et al (2005). A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer, 92, 1644-9. DOI |
5 | Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47. DOI |
6 | Ferlay J, Soerjomataram I, Dikshit R, et al (2014). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. |
7 | Glimelius B, Ekstrom K, Hoffman K, et al (1997). Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol, 8, 163-8. DOI |
8 | Hwang WS, Chao TY, Lin SF, et al (2008). Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer. Anticancer Drugs, 19, 283-8. DOI |
9 | Kim HS, Kim JH, Kim HJ, et al (2012). Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status. Oncol Lett, 3, 425-8. |
10 | Lee HH, Hur H, Kim SH, et al (2010). Outcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysis. Cancer Res Treat, 42, 18-23. DOI |
11 | Liu J, Huang XE, Feng JF (2014). Further study on pemetrexed based chemotherapy in treating patients with advanced gastric cancer (AGC). Asian Pac J Cancer Prev, 15, 6587-90 DOI |
12 | Lordick F, Lorenzen S, Stollfuss J, et al (2005). Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer, 93, 190-4. DOI |
13 | Louvet C, Andre T, Tigaud JM, et al (2002). Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol, 20, 4543-8. DOI |
14 | Luo HY, Xu RH, Zhang L, et al (2008). A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer. Chemotherapy, 54, 228-35. DOI |
15 | Miller RJ (1989). The role of chemotherapy in the hospice patient. A problem of definition. Am J Hosp Care, 6, 19-26. |
16 | Pyrhonen S, Kuitunen T, Nyandoto P, et al (1995). Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer, 71, 587-91. DOI |
17 | Wagner AD, Grothe W, Haerting J, et al (2006). Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol, 24, 2903-9. DOI |
18 | Shitara K, Muro K, Matsuo K, et al (2009). Chemotherapy for patients with advanced gastric cancer with performance status 2. Gastrointest Cancer Res, 3, 220-4. |
19 | Siegel R, Ma J, Zou Z, et al (2014). Cancer statistics, 2014. CA Cancer J Clin, 64, 9-29. DOI |
20 | Sumpter K, Harper-Wynne C, Cunningham D, et al (2005). Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer, 92, 1976-83. DOI |
21 | Bilici A, Selcukbiricik F, Demin N, et al (2015). Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer. Asian Pac J Cancer Prev, 15, 8661-6 |
22 | Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al (2004). Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol, 22, 658-63. DOI |
23 | Bernards N, Creemers GJ, Nieuwenhuijzen GA, et al (2013). No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Ann Oncol, 24, 3056-60. DOI |
24 | Bleiberg H, de Gramont A (1998). Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin Oncol, 25, 32-9. |
25 | Cavanna L, Artioli F, Codignola C, et al (2006). Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC). Am J Clin Oncol, 29, 371-5. DOI |
26 | Chang YR, Han DS, Kong SH, et al (2012). The value of palliative gastrectomy in gastric cancer with distant metastasis. Ann Surg Oncol, 19, 1231-9. DOI |